key: cord-0737324-gdfzqulp authors: Liao, Shu-Chen; Shao, Shih-Chieh; Chen, Yih-Ting; Chen, Yung-Chang; Hung, Ming-Jui title: Incidence and mortality of pulmonary embolism in COVID-19: a systematic review and meta-analysis date: 2020-07-27 journal: Crit Care DOI: 10.1186/s13054-020-03175-z sha: 0a11a62372ae38f658c542b42a727f44f85e150e doc_id: 737324 cord_uid: gdfzqulp nan discussion and only after reaching full agreement. All statistical analyses were performed using MedCalc (Windows) version 15.0 (MedCalc Software, Ostend, Belgium). Incidence and mortality rates of PE in COVID-19 are represented as proportions with 95% confidence interval (CI), using the random effects model, and displayed as Forest plot. Heterogeneity among the studies was detected by Cochran Q test, whereby a p value < 0.10 indicated significant heterogeneity. We assessed the proportion of variation in study estimates attributable to heterogeneity through the I 2 statistic. We excluded 78 out of 97 articles screened: 20 studies were duplicates, 5 were irrelevant, 3 were conference abstracts, 21 were other types of publications, 28 lacked data on PE incidence or mortality, and 1 was published in French. Ultimately, our analysis included 19 articles, mostly from Europe (84%), and we summarize their demographic data in Table 1 . Overall, the incidence and mortality rate of COVID-19 patients developing PE was 15.3% (95%: 9.8-21.9) and 45.1% (95%: 22.0-69.4), respectively. Some evidence of statistical heterogeneity among the studies reporting PE incidence (I 2 : 92.0%, p < 0.001) and mortality (I 2 : 78.6%, p < 0.001) in COVID-19 was observed (Fig. 1) . With increasing reports of PE following COVID-19 infection, our findings indicate that nearly 2 in 10 developed PE among a total of 1835 COVID-19 patients. Immobilization, inflammation, activated coagulation, and suppressed fibrinolysis have been proposed to explain the occurrence of PE in COVID-19 patients; however, the incidence of PE in COVID-19 patients is higher than in patients with seasonal and pandemic influenza (3%) [21] . In addition, our report indicates COVID-19 patients with PE may have up to 45% higher mortality rate compared to general cases (in-hospital mortality rate 4%) [22] . Therefore, first-line healthcare providers should be vigilant about the occurrence of severe and potentially fatal PE complications in COVID-19 patients [23] . As far as we know, this systematic review is the first summarizing PE incidence and mortality in COVID-19 patients. However, caution is advised in interpreting our findings. First, most published literatures are observational studies, making it difficult to confirm causality between COVID-19 and PE. Second, clinical heterogeneity between studies is noteworthy; for example, the included studies apply different diagnostic tools of varying sensitivity and specificity to investigate PE incidence. In conclusion, prevention and control of COVID-19 remains paramount in the current pandemic, but repeated assessment and optimal management of PE complications may significantly modify the prognosis and reduce mortality in patients with COVID-19 [24] . Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Heparin-induced Thrombocytopenia with Thrombosis in COVID-19 Adult Respiratory Distress Syndrome Hip Fracture Outcomes During the COVID-19 Pandemic: Early Results From New York Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction Pulmonary embolism in patients with Covid-19 pneumonia Severe pulmonary embolism in COVID-19 patients: a call for increased awareness Systematic assessment of venous thromboembolism in COVID 19 patients receiving thromboprophylaxis: incidence and role of D dimer as predictive factors Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Pulmonary Embolism in Patients With COVID-19: Awareness of an increased prevalence Acute pulmonary embolism in non-hospitalized COVID-19 patients referred to CTPA by emergency department Venous thromboembolism in critically Ill patients with COVID-19: Results of a screening study for deep vein thrombosis Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography Complications of seasonal and pandemic influenza Pulmonary embolism hospitalization, readmission, and mortality rates in US older adults Our recommendations for acute management of COVID-19 Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations None.Authors' contributions SCL and SCS contributed equally to this work. SCL and SCS: critical analysis, interpretation of the data, and drafting of the manuscript. MJH and YCC: study supervision and administrative, technical, or material support. All authors read and approved the final manuscript. This research is supported by the Chang Gung Memorial Hospital Research Project CLRPG 2J0011.